In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Shire licenses New River's ADHD candidate

Executive Summary

Shire Pharmaceuticals Group PLC licensed exclusive worldwide rights to develop and commercialize New River Pharmaceuticals' NRP104 for attention deficit hyperactivity disorder (ADHD) and possibly other indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register